September 15, 2023
Genethon assesses a therapeutic potential of a Dual AAV vector approach for Duchenne muscular dystrophy
In a study published in the International Journal of Molecular Sciences on July 13th, Genethon’s researcher Sonia Albini, deployed a dual AAV approach to deliver quasidystrophin.
(read more)September 11, 2023
Genethon’s Optidys project rewarded by BpiFrance as part of France 2030
Genethon’s Optidys project is rewarded in response to the call for proposals “Innovation in Biotherapies and Bioproduction” led by BPIfrance as part of France 2030.
(read more)September 4, 2023
Genethon researchers involved in the MAGIC international consortium
Three Genethon experts are participating in the MAGIC project (Next-generation Models and Genetic therapIes for rare neuromusCular diseases), dedicated to the development of innovative therapeutic strategies in muscular dystrophies.
(read more)June 14, 2023
”A milestone in gene therapy: proof of long-term efficacy”
Frédéric Revah, CEO of Genethon discusses Genethon’s major contribution to therapeutic innovation
(read more)May 30, 2023
Research work carried out at Genethon rewarded at the 26th edition of the ASGCT
Ai vu Hong, Research Fellow, and Laura Palmieri, PhD student, both members of Généthon’s progressive muscular dystrophies team, led by Isabelle Richard, received awards at the ASGCT 2023 congress held in Los Angeles from May 16 to 20.
(read more)February 24, 2023
Chronic septic granulomatosis: biomarkers predict the efficacy of gene therapy
In a gene therapy trial promoted by Genethon, teams from Necker children’s hospital working with teams from Inserm and Université Paris Cité, at Institut Imagine, have identified 51 biomarkers that could predict the success of this treatment.
(read more)February 7, 2023
“We made important achievements in 2022 but we still face key challenges in the year ahead”
Frédéric Revah, CEO of Genethon looks back on the year 2022 marked by major advances for gene therapy and presents the challenges ahead in 2023
(read more)January 10, 2023
Genethon Launches Pivotal Clinical Trial of Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease
The gene therapy would represent a first-of-its kind treatment for this life threatening genetic disease.
(read more)December 14, 2022
Publication: Genethon helps clarify a molecular mechanism of mitochondrial malfunction in Duchenne muscular dystrophy
… (read more)November 21, 2022
Téléthon 2022: Benjamin, a hope for families thanks to clinical trials
… (read more)Telethon 2022: for Lucie, “a real opportunity, thanks to advances in research”
… (read more)October 5, 2022
Publication: Genethon helps identify two vectors optimized for muscles via a European H2020 program
… (read more)September 26, 2022
